![In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer— But at FDA “Maybe” has meaning](https://cdn.cancerletter.com/media/2017/09/tie-web2.jpg)
![In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer— But at FDA “Maybe” has meaning](https://cdn.cancerletter.com/media/2017/09/tie-web2.jpg)
Cover Story
In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—
But at FDA “Maybe” has meaningWith frustrating photo finish voting results—6-6—still on the screen, FDA's cancer czar Richard Pazdur delivered an acerbic thank-you to members of the agency's Oncologic Drugs Advisory Committee:“Well, that's the end vote, it makes our job definitely easier,” said Pazdur, director of the FDA's Oncology Center of Excellence, who gets sarcastic sometimes.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets
Trending Stories
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” - UChicago Cancer Luminaries Podcast: Todd Golub discusses mentorship, interdisciplinary research